News Related to Lean Mass

Related coverage linked through entity extraction aliases.

Veru Enrolls First Patient in Phase 2b PLATEAU Trial of Enobosarm Plus Semaglutide

Mar 09, 2026

Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for weight loss in older patients with obesity. The study will assess enobosarm's ability to preserve lean mass and physical function while augmenting fat loss.

GLP-1 Drugs Effective in Rare Genetic Obesity, Mouse Study Shows

Mar 01, 2026

Three GLP-1 weight-loss drugs—semaglutide, tirzepatide and retatrutide—reduced weight and improved metabolic health in mice lacking the MC4R gene, offering potential treatment for rare genetic obesity.